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LETTERS TO THE EDITORRegarding “Balloon control of the saphenofemoral
junction during foam sclerotherapy: Proposed
innovation”
In the article by Bidwai et al,1 the authors report on utilizing
perforator ligation and a balloon catheter to occlude the saphe-
nofemoral junction during foam sclerotherapy of the great saphe-
nous vein. Several objections to this method of saphenous vein
ablation deserve mention.
It appears that all thigh and proximal leg perforators identified
by duplex scan were systematically ligated, no matter their flow
characteristics. Presumably, this resulted in occlusion of at least
some perfectly normal perforator veins. The rationale for the
sacrifice of normal veins to theoretically prevent foam escaping into
the deep venous system is flawed, since the perforators seen by
duplex scan represent only a minority of the actual number of
perforator veins in the leg. Furthermore, following removal of the
saphenous vein from the venous circulation, previously incompe-
tent perforators will often become competent.2 A priori destruc-
tion of normal or even incompetent perforators is meddlesome at
best.
It also appears that there was no duplex examination during
foam injection to prove foam did not progress into the deep venous
system. Consequently, the claim that perforator ligation and prox-
imal saphenous vein occlusion successfully prevented foam enter-
ing the deep venous system is simply not justifiable. Had the
authors performed intraoperative duplex examination of the deep
venous system, simultaneous transthoracic echocardiography, or
transcranial Doppler monitoring during injection, as we have done
in our center, they would have noted foam progressing not only
into the deep venous system, but into the central circulation and
indeed into the cerebral circulation in patients with right-to-left
shunts (estimated to be over 25% of the normal population).3
Further, occlusion of the proximal saphenous vein, rather than
preventing progression of foam into the deep venous system,
actually encourages flow into deep veins, because it is prevented
from progressing gradually through the saphenofemoral junction
and is forced into perforator veins. This was also proven in our
center using a different balloon-tipped catheter with simultaneous
foam injection and ultrasound examination of the deep venous
system, particularly the common femoral vein.
Additionally, on release of the balloon, there will be an imme-
diate bolus of foam into the deep venous system which progresses
to the heart. It is muchmore likely that a bolus of foam bubbles will
progress through a right-to-left shunt, such as a patent foramen
ovale, than bubbles that gradually migrate to the heart as following
foam injection of a nonoccluded great saphenous vein. It is pre-
cisely for this reason that an occlusion balloon-tipped catheter is
rarely used in European countries wherein chemical foam ablation
is commonly performed (specifically Germany, France, Italy, and
the United Kingdom).
Finally, using simultaneous transthoracic echocardiography
and/or transcranial Doppler monitoring of the middle cerebral
artery during ultrasound guided foam sclerotherapy, we haveshown that the use any of the suggested methods to prevent
migration of at least some bubbles from the injected superficial
vein into the deep venous system and beyond (eg, leg elevation,
small foam volumes, postinjection rest) is simply ineffective. Com-
plications such as deep venous thrombosis and systemic symptoms
will occur at a certain (albeit low) rate, and asserting that use of an
occlusive balloon and ligation of a few perforators will prevent such
complications is wishful thinking.
Nick Morrison, MD
Morrison Vein Institute
Scottsdale, Ariz
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Regarding “The role of catheter-directed lytic therapy
in patients with popliteal artery aneurysms and acute
limb ischemia”
We read with interest the article on popliteal artery aneurysms
(PAAs) by Huang et al.1 The role of catheter-directed lytic therapy
in the patients with acute limb ischemia was unclear, a fact noted in
Huber’s invited commentary.
We have found a guideline that we believe to be extremely
useful. If the clot extends into and occludes the trifurcation arteries
from a recently thrombosed PAA, catheter-directed lytic therapy
can be very useful. However, if only the PAA is thrombosed, with
patent trifurcation arteries, lytic therapy is not indicated. We
learned this lesson the hard way. A middle-aged man presented to
us with acute thrombosis of a PAA. The distal popliteal artery and
all three trifurcation arteries were widely patent. After 4 hours of
intra-PAA lytic therapy, a popliteal thrombus embolized and oc-
cluded all three trifurcation arteries, resulting in markedly in-
creased ischemia. Limb loss resulted. If only the PAA is throm-
bosed, one has nothing to gain and everything to lose by using
catheter-based lytic therapy.
Douglas C. Smith, MD
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